Key result
Paclitaxel- and sirolimus-coated balloons show similar 1-year target lesion failure rates.
Why the study?
Potential differences in clinical outcomes by drug class and device among contemporary coronary drug-coated balloons required exploration.
Does percutaneous coronary intervention with sirolimus-coated balloons vs paclitaxel-coated balloons (and different device platforms within each class) reduce 1-year target lesion failure in all-comer patients undergoing DCB-based PCI?
Observational (n=1,018)
Yes
Does percutaneous coronary intervention with sirolimus-coated balloons vs paclitaxel-coated balloons (and different device platforms within each class) reduce 1-year target lesion failure in all-comer patients undergoing DCB-based PCI?
In a real-world multicenter cohort, paclitaxel- and sirolimus-coated coronary balloons demonstrated comparable 1-year target lesion failure rates, although exploratory analysis suggested significant device-specific differences between microreservoir-based and nanoparticle-based sirolimus platforms.
Answers are grounded in this paper and cite their sources.
Supports equivalent paclitaxel- and sirolimus-coated balloon use in real-world DCB PCI; sirolimus platform differences remain hypothesis-generating.
Introduction and objectives: To explore potential differences by drug class and device among contemporary coronary drug-coated balloons (DCBs). Methods: We conducted a national, 4-center, observational, retrospective study including all-comer patients undergoing DCB-based percutaneous coronary intervention between January 2023 and December 2024. Patients treated with more than 1 DCB brand were excluded. Patients were followed up for 1 year. The primary endpoint was target lesion failure (TLF), defined as a composite of cardiac death, target vessel-related myocardial infarction (TVMI), and clinically driven target lesion revascularization (TLR). To assess drug- and device-level effects, inverse probability of treatment weighting based on propensity scores was applied, and outcomes were analyzed using Cox proportional hazards models with clustering at the patient level. Results: A total of 1018 patients (1359 lesions) were included. At 1 year, TLF rates were similar between paclitaxel- and sirolimus-coated balloons (6.2% vs 4.6%; P = .204), with no significant difference after adjustment (HR, 1.22; 95%CI, 0.71–2.10; P = .474). Among paclitaxel-coated balloons, no significant differences in TLF were observed across the 3 devices. In contrast, among sirolimus-coated balloons, treatment with a microreservoir-based balloon was associated with a lower observed risk of TLF compared with a nanoparticle-based balloon (HR, 0.17; 95%CI, 0.05–0.58; P = .004). Conclusions: In this real-world multicenter study, paclitaxel- and sirolimus-coated balloons showed comparable 1-year outcomes. While paclitaxel devices demonstrated consistent performance across platforms, outcomes differed among sirolimus-coated balloons. The device-level findings should be considered exploratory and hypothesis-generating because of the limited number of events and the residual risk of confounding. Keywords: Drug-coated balloons. Sirolimus. Paclitaxel. Coronary artery disease. Percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Faria et al. (2026) conducted an observational in Coronary artery disease undergoing drug-coated balloon PCI (n=1,018). Paclitaxel-coated balloon vs. Sirolimus-coated balloon was evaluated on Target lesion failure (TLF), a composite of cardiac death, target vessel-related myocardial infarction (TVMI), and clinically driven target lesion revascularization (TLR) (HR 1.22, 95% CI 0.71-2.10, p=0.474). Paclitaxel- and sirolimus-coated balloons had similar 1-year target lesion failure rates, though device-level outcomes varied for sirolimus.
Synapse has enriched 10 related papers. Consider them for comparative context: